Last reviewed · How we verify
Canagliflozin (JNJ-28431754)
Canagliflozin (JNJ-28431754) is a SGLT2 inhibitor Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. It is currently in Phase 3 development for Type 2 diabetes mellitus. Also known as: JNJ-28431754.
Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing reabsorption of glucose and promoting urinary glucose excretion to lower blood glucose levels.
Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing reabsorption of glucose and promoting urinary glucose excretion to lower blood glucose levels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Canagliflozin (JNJ-28431754) |
|---|---|
| Also known as | JNJ-28431754 |
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SGLT2 is responsible for reabsorbing filtered glucose in the proximal tubule of the nephron. By blocking this transporter, canagliflozin allows glucose to be excreted in the urine rather than reabsorbed into the bloodstream, thereby reducing hyperglycemia. This mechanism is independent of insulin secretion or action, making it effective across different stages of type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Thirst
- Diabetic ketoacidosis
Key clinical trials
- A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment (PHASE1)
- Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus (PHASE3)
- An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes (PHASE2)
- Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes (PHASE3)
- A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus (PHASE3)
- A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure (PHASE3)
- A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes (PHASE4)
- Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Canagliflozin (JNJ-28431754) CI brief — competitive landscape report
- Canagliflozin (JNJ-28431754) updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI
Frequently asked questions about Canagliflozin (JNJ-28431754)
What is Canagliflozin (JNJ-28431754)?
How does Canagliflozin (JNJ-28431754) work?
What is Canagliflozin (JNJ-28431754) used for?
Who makes Canagliflozin (JNJ-28431754)?
Is Canagliflozin (JNJ-28431754) also known as anything else?
What drug class is Canagliflozin (JNJ-28431754) in?
What development phase is Canagliflozin (JNJ-28431754) in?
What are the side effects of Canagliflozin (JNJ-28431754)?
What does Canagliflozin (JNJ-28431754) target?
Related
- Drug class: All SGLT2 inhibitor drugs
- Target: All drugs targeting SGLT2 (sodium-glucose cotransporter 2)
- Manufacturer: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: JNJ-28431754
- Compare: Canagliflozin (JNJ-28431754) vs similar drugs
- Pricing: Canagliflozin (JNJ-28431754) cost, discount & access